Translational Research Techniques for the Facial Plastic Surgeon: An Overview

Abstract

The field of facial plastic and reconstructive surgery (FPRS) is an incredibly diverse, multispecialty field that seeks innovative and novel solutions for the management of physical defects on the head and neck. To aid in the advancement of medical and surgical treatments for these defects, there has been a recent emphasis on the importance of translational research. With recent technological advancements, there are now a myriad of research techniques that are widely accessible for physician and scientist use in translational research. Such techniques include integrated multiomics, advanced cell culture and microfluidic tissue models, established animal models, and emerging computer models generated using bioinformatics. This study discusses these various research techniques and how they have and can be used for research in the context of various important diseases within the field of FPRS.

Keywords

translational research - multiomics - facial plastic and reconstructive surgery - keloid disease

Publication History

Accepted Manuscript online:
20 June 2023

Article published online:
20 July 2023

• References

• 1 Bhattacharya S. Jacques Joseph: father of modern aesthetic surgery. Indian J Plast Surg 2008; 41 (Suppl): S3-S8
• 2 Bersanelli M, Mosca E, Remondini D. et al. Methods for the integration of multi-omics data: mathematical aspects. BMC Bioinformatics 2016; 17 (Suppl. 02) 15
• 3 Bock C, Farlik M, Sheffield NC. Multi-omics of single cells: strategies and applications. Trends Biotechnol 2016; 34 (08) 605-608
• 4 Vilanova C, Porcar M. Are multi-omics enough?. Nat Microbiol 2016; 1 (08) 16101
• 5 National Cancer Institute (US). Dictionary of Cancer Terms. Bethesda, MD: National Cancer Institute; US; 2002. Accessed June 19, 2023 at: https://www.ncbi.nlm.nih.gov/books/NBK65951/
• 6 Wilkie AO, Slaney SF, Oldridge M. et al. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet 1995; 9 (02) 165-172
• 7 Scambler PJ, Kelly D, Lindsay E. et al. Velo-cardio-facial syndrome associated with chromosome 22 deletions encompassing the DiGeorge locus. Lancet 1992; 339 (8802): 1138-1139
• 8 Glass II DA. Current understanding of the genetic causes of keloid formation. J Investig Dermatol Symp Proc 2017; 18 (02) S50-S53
• 9 Durmaz AA, Karaca E, Demkow U, Toruner G, Schoumans J, Cogulu O. Evolution of genetic techniques: past, present, and beyond. BioMed Res Int 2015; 2015: 461524
• 10 Halim AS, Emami A, Salahshourifar I, Kannan TP. Keloid scarring: understanding the genetic basis, advances, and prospects. Arch Plast Surg 2012; 39 (03) 184-189
• 11 Ahmed A, Almohanna H, Griggs J, Tosti A. Genetic hair disorders: a review. Dermatol Ther (Heidelb) 2019; 9 (03) 421-448
• 12 Makrantonaki E, Bekou V, Zouboulis CC. Genetics and skin aging. Dermatoendocrinol 2012; 4 (03) 280-284
• 13 Dixon MJ, Marazita ML, Beaty TH, Murray JC. Cleft lip and palate: understanding genetic and environmental influences. Nat Rev Genet 2011; 12 (03) 167-178
• 14 Butali A, Mossey PA, Adeyemo WL. et al. Genomic analyses in African populations identify novel risk loci for cleft palate. Hum Mol Genet 2019; 28 (06) 1038-1051
• 15 Grant SF, Wang K, Zhang H. et al. A genome-wide association study identifies a locus for nonsyndromic cleft lip with or without cleft palate on 8q24. J Pediatr 2009; 155 (06) 909-913
• 16 Birnbaum S, Ludwig KU, Reutter H. et al. Key susceptibility locus for nonsyndromic cleft lip with or without cleft palate on chromosome 8q24. Nat Genet 2009; 41 (04) 473-477
• 17 Mangold E, Ludwig KU, Birnbaum S. et al. Genome-wide association study identifies two susceptibility loci for nonsyndromic cleft lip with or without cleft palate. Nat Genet 2010; 42 (01) 24-26
• 18 Beaty TH, Murray JC, Marazita ML. et al. A genome-wide association study of cleft lip with and without cleft palate identifies risk variants near MAFB and ABCA4. Nat Genet 2010; 42 (06) 525-529
• 19 Ludwig KU, Mangold E, Herms S. et al. Genome-wide meta-analyses of nonsyndromic cleft lip with or without cleft palate identify six new risk loci. Nat Genet 2012; 44 (09) 968-971
• 20 Sun Y, Huang Y, Yin A. et al. Genome-wide association study identifies a new susceptibility locus for cleft lip with or without a cleft palate. Nat Commun 2015; 6: 6414
• 21 Leslie EJ, Carlson JC, Shaffer JR. et al. A multi-ethnic genome-wide association study identifies novel loci for non-syndromic cleft lip with or without cleft palate on 2p24.2, 17q23 and 19q13. Hum Mol Genet 2016; 25 (13) 2862-2872
• 22 Leslie EJ, Liu H, Carlson JC. et al. A genome-wide association study of nonsyndromic cleft palate identifies an etiologic missense variant in GRHL3. Am J Hum Genet 2016; 98 (04) 744-754
• 23 Mangold E, Böhmer AC, Ishorst N. et al. Sequencing the GRHL3 coding region reveals rare truncating mutations and a common susceptibility variant for nonsyndromic cleft palate. Am J Hum Genet 2016; 98 (04) 755-762
• 24 Leslie EJ, Carlson JC, Shaffer JR. et al. Genome-wide meta-analyses of nonsyndromic orofacial clefts identify novel associations between FOXE1 and all orofacial clefts, and TP63 and cleft lip with or without cleft palate. Hum Genet 2017; 136 (03) 275-286
• 25 Ludwig KU, Ahmed ST, Böhmer AC. et al. Meta-analysis reveals genome-wide significance at 15q13 for nonsyndromic clefting of both the lip and the palate, and functional analyses implicate GREM1 as a plausible causative gene. PLoS Genet 2016; 12 (03) e1005914
• 26 Yu Y, Zuo X, He M. et al. Genome-wide analyses of non-syndromic cleft lip with palate identify 14 novel loci and genetic heterogeneity. Nat Commun 2017; 8: 14364
• 27 Shabalina SA, Spiridonov NA. The mammalian transcriptome and the function of non-coding DNA sequences. Genome Biol 2004; 5 (04) 105
• 28 Lowe R, Shirley N, Bleackley M, Dolan S, Shafee T. Transcriptomics technologies. PLOS Comput Biol 2017; 13 (05) e1005457
• 29 Stark R, Grzelak M, Hadfield J. RNA sequencing: the teenage years. Nat Rev Genet 2019; 20 (11) 631-656
• 30 Zou Z, Tao T, Li H, Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci 2020; 10: 31
• 31 Wong VW, You F, Januszyk M, Gurtner GC, Kuang AA. Transcriptional profiling of rapamycin-treated fibroblasts from hypertrophic and keloid scars. Ann Plast Surg 2014; 72 (06) 711-719
• 32 Dupont C, Armant DR, Brenner CA. Epigenetics: definition, mechanisms and clinical perspective. Semin Reprod Med 2009; 27 (05) 351-357
• 33 Jones LR, Young W, Divine G. et al. Genome-wide scan for methylation profiles in keloids. Dis Markers 2015; 2015: 943176
• 34 Simeone P, Alberti S. Epigenetic heredity of human height. Physiol Rep 2014; 2 (06) e12047
• 35 Lim JP, Brunet A. Bridging the transgenerational gap with epigenetic memory. Trends Genet 2013; 29 (03) 176-186
• 36 Gapp K, Jawaid A, Sarkies P. et al. Implication of sperm RNAs in transgenerational inheritance of the effects of early trauma in mice. Nat Neurosci 2014; 17 (05) 667-669
• 37 Iqbal K, Tran DA, Li AX. et al. Deleterious effects of endocrine disruptors are corrected in the mammalian germline by epigenome reprogramming. Genome Biol 2015; 16 (01) 59
• 38 Shea JM, Serra RW, Carone BR. et al. Genetic and epigenetic variation, but not diet, shape the sperm methylome. Dev Cell 2015; 35 (06) 750-758
• 39 Kaati G, Bygren LO, Pembrey M, Sjöström M. Transgenerational response to nutrition, early life circumstances and longevity. Eur J Hum Genet 2007; 15 (07) 784-790
• 40 Bartel DP. Metazoan microRNAs. Cell 2018; 173 (01) 20-51
• 41 Baker MA, Davis SJ, Liu P. et al. Tissue-specific microRNA expression patterns in four types of kidney disease. J Am Soc Nephrol 2017; 28 (10) 2985-2992
• 42 Tang W, Wan S, Yang Z, Teschendorff AE, Zou Q. Tumor origin detection with tissue-specific miRNA and DNA methylation markers. Bioinformatics 2018; 34 (03) 398-406
• 43 Zhang J, Xu D, Li N. et al. Downregulation of microRNA-31 inhibits proliferation and induces apoptosis by targeting HIF1AN in human keloid. Oncotarget 2017; 8 (43) 74623-74634
• 44 Li C, Bai Y, Liu H. et al. Comparative study of microRNA profiling in keloid fibroblast and annotation of differential expressed microRNAs. Acta Biochim Biophys Sin (Shanghai) 2013; 45 (08) 692-699
• 45 Zhu C, Wang S, Zheng M. et al. miR-31-5p modulates cell progression in lung adenocarcinoma through TNS1/p53 axis. Strahlenther Onkol 2022; 198 (03) 304-314
• 46 Fu H, Zhou F, Yuan Q. et al. miRNA-31-5p mediates the proliferation and apoptosis of human spermatogonial stem cells via targeting JAZF1 and cyclin A2. Mol Ther Nucleic Acids 2019; 14: 90-100
• 47 Lu Z, He Q, Liang J. et al. miR-31-5p is a potential circulating biomarker and therapeutic target for oral cancer. Mol Ther Nucleic Acids 2019; 16: 471-480
• 48 Liu CJ, Tsai MM, Hung PS. et al. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res 2010; 70 (04) 1635-1644
• 49 Lei SL, Zhao H, Yao HL. et al. Regulatory roles of microRNA-708 and microRNA-31 in proliferation, apoptosis and invasion of colorectal cancer cells. Oncol Lett 2014; 8 (04) 1768-1774
• 50 Wang A, Landén NX, Meisgen F. et al. MicroRNA-31 is overexpressed in cutaneous squamous cell carcinoma and regulates cell motility and colony formation ability of tumor cells. PLoS One 2014; 9 (07) e103206
• 51 Laurila EM, Kallioniemi A. The diverse role of miR-31 in regulating cancer associated phenotypes. Genes Chromosomes Cancer 2013; 52 (12) 1103-1113
• 52 Li Y, Quan J, Chen F. et al. MiR-31-5p acts as a tumor suppressor in renal cell carcinoma by targeting cyclin-dependent kinase 1 (CDK1). Biomed Pharmacother 2019; 111: 517-526
• 53 Wang S, Hu J, Zhang D, Li J, Fei Q, Sun Y. Prognostic role of microRNA-31 in various cancers: a meta-analysis. Tumour Biol 2014; 35 (11) 11639-11645
• 54 Wei J, Wang Z, Wang Z. et al. MicroRNA-31 function as a suppressor was regulated by epigenetic mechanisms in gastric cancer. BioMed Res Int 2017; 2017: 5348490
• 55 Peng B, Chen Y, Leong KW. MicroRNA delivery for regenerative medicine. Adv Drug Deliv Rev 2015; 88: 108-122
• 56 Turker MS. Gene silencing in mammalian cells and the spread of DNA methylation. Oncogene 2002; 21 (35) 5388-5393
• 57 Stephen JK, Vaught LE, Chen KM. et al. An epigenetically derived monoclonal origin for recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2007; 133 (07) 684-692
• 58 Stephen JK, Chen KM, Shah V. et al. Consistent DNA hypermethylation patterns in laryngeal papillomas. Int J Head Neck Surg 2010; 1 (02) 69-77
• 59 Worsham MJ, Stephen JK, Chen KM. et al. Delineating an epigenetic continuum in head and neck cancer. Cancer Lett 2014; 342 (02) 178-184
• 60 Pease M, Ling C, Mack WJ, Wang K, Zada G. The role of epigenetic modification in tumorigenesis and progression of pituitary adenomas: a systematic review of the literature. PLoS One 2013; 8 (12) e82619
• 61 Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128 (04) 683-692
• 62 Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3 (06) 415-428
• 63 Jones LR, Greene J, Chen KM. et al. Biological significance of genome-wide DNA methylation profiles in keloids. Laryngoscope 2017; 127 (01) 70-78
• 64 Alghamdi MA, Wallace HJ, Melton PE. et al. Identification of differentially methylated CpG sites in fibroblasts from keloid scars. Biomedicines 2020; 8 (07) 181
• 65 Stevenson AW, Deng Z, Allahham A, Prêle CM, Wood FM, Fear MW. The epigenetics of keloids. Exp Dermatol 2021; 30 (08) 1099-1114
• 66 Smith CM, Haimberger ZW, Johnson CO. et al. Heritable chromatin structure: mapping “memory” in histones H3 and H4. Proc Natl Acad Sci U S A 2002; 99 (Suppl. 04) 16454-16461
• 67 Russell SB, Russell JD, Trupin KM. et al. Epigenetically altered wound healing in keloid fibroblasts. J Invest Dermatol 2010; 130 (10) 2489-2496
• 68 Glenisson W, Castronovo V, Waltregny D. Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim Biophys Acta 2007; 1773 (10) 1572-1582
• 69 Ghosh AK, Mori Y, Dowling E, Varga J. Trichostatin A blocks TGF-beta-induced collagen gene expression in skin fibroblasts: involvement of Sp1. Biochem Biophys Res Commun 2007; 354 (02) 420-426
• 70 Rombouts K, Niki T, Greenwel P. et al. Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta(1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res 2002; 278 (02) 184-197
• 71 Huber LC, Distler JH, Moritz F. et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum 2007; 56 (08) 2755-2764
• 72 Hsu CK, Lin HH, Harn HI. et al. Caveolin-1 controls hyperresponsiveness to mechanical stimuli and fibrogenesis-associated RUNX2 activation in keloid fibroblasts. J Invest Dermatol 2018; 138 (01) 208-218
• 73 Jian X, Qu L, Wang Y. et al. Trichostatin A-induced miR-30a-5p regulates apoptosis and proliferation of keloid fibroblasts via targeting BCL2. Mol Med Rep 2019; 19 (06) 5251-5262
• 74 Tu T, Huang J, Lin M. et al. CUDC-907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2. Int J Mol Med 2019; 44 (05) 1789-1800
• 75 Yoon S, Kang G, Eom GH. HDAC inhibitors: therapeutic potential in fibrosis-associated human diseases. Int J Mol Sci 2019; 20 (06) 1329
• 76 Hiebert CA. The carcinogenic action of methylcholanthrene on mouse skin in organ culture. Cancer 1959; 12 (04) 663-672
• 77 Bell E, Ivarsson B, Merrill C. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc Natl Acad Sci U S A 1979; 76 (03) 1274-1278
• 78 Yin B, Ni J, Witherel CE. et al. Harnessing tissue-derived extracellular vesicles for osteoarthritis theranostics. Theranostics 2022; 12 (01) 207-231
• 79 Amsar RM, Wijaya CH, Ana ID. et al. Extracellular vesicles: a promising cell-free therapy for cartilage repair. Future Sci OA 2021; 8 (02) FSO774
• 80 Bajada S, Mazakova I, Richardson JB, Ashammakhi N. Updates on stem cells and their applications in regenerative medicine. J Tissue Eng Regen Med 2008; 2 (04) 169-183
• 81 Schmidt C. FDA approves first cell therapy for wrinkle-free visage. Nat Biotechnol 2011; 29 (08) 674-675
• 82 Eça LP, Pinto DG, de Pinho AM, Mazzetti MP, Odo ME. Autologous fibroblast culture in the repair of aging skin. Dermatol Surg 2012; 38 (02) 180-184
• 83 Khodadadi L, Shafieyan S, Sotoudeh M. et al. Intraepidermal injection of dissociated epidermal cell suspension improves vitiligo. Arch Dermatol Res 2010; 302 (08) 593-599
• 84 Kim JH, Jung M, Kim HS, Kim YM, Choi EH. Adipose-derived stem cells as a new therapeutic modality for ageing skin. Exp Dermatol 2011; 20 (05) 383-387
• 85 Leung CM, de Haan P, Ronaldson-Bouchard K. et al. A guide to the organ-on-a-chip. Nat Rev Methods Primers 2022; 2: 33
• 86 Amirifar L, Shamloo A, Nasiri R. et al. Brain-on-a-chip: recent advances in design and techniques for microfluidic models of the brain in health and disease. Biomaterials 2022; 285: 121531
• 87 Van Gele M, Geusens B, Brochez L, Speeckaert R, Lambert J. Three-dimensional skin models as tools for transdermal drug delivery: challenges and limitations. Expert Opin Drug Deliv 2011; 8 (06) 705-720
• 88 Küchler S, Strüver K, Friess W. Reconstructed skin models as emerging tools for drug absorption studies. Expert Opin Drug Metab Toxicol 2013; 9 (10) 1255-1263
• 89 Flaten GE, Palac Z, Engesland A, Filipović-Grčić J, Vanić Ž, Škalko-Basnet N. In vitro skin models as a tool in optimization of drug formulation. Eur J Pharm Sci 2015; 75: 10-24
• 90 Zhang Q, Sito L, Mao M, He J, Zhang YS, Zhao X. Current advances in skin-on-a-chip models for drug testing. Microphysiol Syst 2018; 2: 4
• 91 Kim K, Kim J, Kim H, Sung GY. Effect of α-lipoic acid on the development of human skin equivalents using a pumpless skin-on-a-chip model. Int J Mol Sci 2021; 22 (04) 2160
• 92 Fetah KL, DiPardo BJ, Kongadzem E-M. et al. Cancer modeling-on-a-chip with future artificial intelligence integration. Small 2019; 15 (50) e1901985
• 93 Elmusrati M, Ashammakhi N. Cancer-on-a-chip and artificial intelligence: tomorrow's cancer management. J Craniofac Surg 2018; 29 (07) 1682-1683
• 94 Abaci HE, Shuler ML. Human-on-a-chip design strategies and principles for physiologically based pharmacokinetics/pharmacodynamics modeling. Integr Biol 2015; 7 (04) 383-391
• 95 Zor F, Bozkurt M, Nair D, Siemionow M. A new composite midface allotransplantation model with sensory and motor reinnervation. Transpl Int 2010; 23 (06) 649-656
• 96 Kulahci Y, Siemionow M. A new composite hemiface/mandible/tongue transplantation model in rats. Ann Plast Surg 2010; 64 (01) 114-121
• 97 Morris DE, Wu L, Zhao LL. et al. Acute and chronic animal models for excessive dermal scarring: quantitative studies. Plast Reconstr Surg 1997; 100 (03) 674-681
• 98 Gupta A, Bhat S, Jagdale PR. et al. Evaluation of three-dimensional chitosan-agarose-gelatin cryogel scaffold for the repair of subchondral cartilage defects: an in vivo study in a rabbit model. Tissue Eng Part A 2014; 20 (23–24): 3101-3111
• 99 Hallermann W, Olsen S, Bardyn T, Taghizadeh F, Banic A, Iizuka T. A new method for computer-aided operation planning for extensive mandibular reconstruction. Plast Reconstr Surg 2006; 117 (07) 2431-2437
• 100 Mohanty AJ, Cleveland P, Shang Z. et al. Facial nerve high-resolution visualization and topographic microanatomy analysis from the distal intratemporal to extracranial pes segment - reconstructive implications. Plast Reconstr Surg 2023; 152 (01) 175-182